Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil

DH Palmer*, 1, AE Milner1, DJ Kerr1, 2 and LS Young1

1CR UK Institute for Cancer Studies, Clinical Research Block, University of Birmingham, Birmingham B15 2TA, UK

Virus-directed enzyme prodrug therapy (VDEPT) utilising the bacterial enzyme nitroreductase delivered by a replication-defective adenovirus vector to activate the prodrug CB1954 is a promising strategy currently undergoing clinical trials in patients with a range of cancers. An understanding of the mechanism of tumour cell death induced by activated CB1954 will facilitate this clinical development. Here, we report that activated CB1954 kills cells predominantly by caspase-dependent apoptosis. This may have important implications for the generation of immune-mediated bystander effects. Further, the use of a replication-defective adenovirus vector to deliver nitroreductase may negatively affect cellular apoptotic pathways stimulated by activated CB1954. Finally, examination of nitroreductase/CB1954 in combination with conventional chemotherapy reveals a synergistic interaction with 5-fluorouracil. These data will facilitate the further development and future clinical trial design of this novel therapy.

British Journal of Cancer (2003) 89, 944 – 950. doi:10.1038/sj.bjc.6601211 www.bjcancer.com

Keywords: VDEPT; nitroreductase; CB1954; apoptosis; synergy; 5-fluorouracil

Epithelial ovarian cancer is the leading cause of death from gynaecological cancer with the majority of patients presenting with advanced intraperitoneal disease and requiring chemotherapy. The current standard treatment is a combination of carboplatin or cisplatin with paclitaxel. However, 5-year survival remains poor at 25 – 30%. It is imperative therefore that novel treatments are developed.

Chemotherapeutic drugs can kill cells by activating apoptotic pathways and the exact mechanism by which this occurs is currently under intense investigation. Initial studies revealed that cytotoxic drugs can activate death receptor/caspase-8 signalling pathways and this mechanism may be an essential factor in the early phase of drug-induced cell death depending on the cell type used (Friesen et al, 1996; Fulda et al, 1997, 1998a, b, 2000; Micheau et al, 1997). However, not all cell types require death receptor–ligand interaction for drugs to be effective (Gamen et al, 1997; Eischen et al, 1997; Villunger et al, 1997; Tolomeo et al, 1998; Ruiz-Ruiz and Lopez-Rivas, 1999). Recent studies have indicated that caspase-8 can be activated independently of death receptor ligand interaction for drugs to be effective (Gamen et al, 1997; Eischen et al, 1997; Villunger et al, 1997; Tolomeo et al, 1998; Ruiz-Ruiz and Lopez-Rivas, 1999). Other potential advantages of the NR/CB1954 combination are the ability to kill cells in a cell cycle-independent manner and the lack of cross-resistance with other commonly used cytotoxic agents (Milner et al, 2002). Interestingly, different drugs may engage distinct components of the apoptotic machinery (Milner et al, 2002). This is important since it may allow the use of different drugs to form potentially synergistic combinations.

A novel approach to cancer therapy currently entering clinical trials is Virus-Directed Enzyme Prodrug Therapy (VDEPT). This utilises an adenovirus delivered enzyme, nitroreductase (NR), to catalyse the conversion of a relatively nontoxic prodrug (CB1954) into an extremely potent DNA cross-linking agent. Preclinical studies have shown that adenoviral delivery of NR to a range of human cancer cell lines sensitises them to CB1954 by 500 – 2000-fold compared to the parental cell line (Weedon et al, 2000). Further, in an in vivo xenograft model of peritoneal pancreatic cancer (Suit 2), a doubling in median survival was seen in mice treated with virus and CB1954 compared to controls (P<0.0001) (Weedon et al, 2000).

In vitro cell mixing experiments using unmodified and NR-expressing ovarian carcinoma cell lines have demonstrated significant sensitisation (30–100-fold) of the total cell population to CB1954 when only 5 – 10% of the cells express NR (McNeil et al, 1998). Similarly, in vivo in a human hepatoma murine xenograft model, a significant antitumour effect and improved survival were observed even when only 5% of cells expressed NR, confirming a significant bystander effect (Djeha et al, 2000). Interestingly, studies of other enzyme–prodrug combinations also suggest a ‘distant bystander effect’ thought to be a systemic immune-mediated response to local tumour cell killing (Link et al, 1997).

Other potential advantages of the NR/CB1954 combination are the ability to kill cells in a cell cycle-independent manner and the lack of cross-resistance with other commonly used cytotoxic agents (Bridgewater et al, 1995; Knox, 1998). A recent phase I clinical trial has confirmed that CB1954 is a well-tolerated prodrug that can be administered intravenously or intraperitoneally at doses sufficient for a VDEPT approach to be feasible in the treatment of ovarian cancer (Chung-Faye et al, 2001). A further clinical trial to assess the safety, tolerability and transgene expression of a replication-deficient adenovirus vector carrying the gene for nitroreductase is ongoing. It is important, therefore, to investigate the mechanism
by which activated CB1954 kills NR-expressing cancer cells. This will facilitate the further clinical development of this system in enhancing distant bystander effects and in devising rational combinations with conventional chemotherapeutic agents.

The aims of the current study are: (1) to determine the mode of cell death initiated by activated CB1954, (2) to identify the apoptotic pathways induced by activated CB1954 and in particular to identify any requirement for caspase activation, and (3) to assess the effect of CB1954 given in combination with a range of other chemotherapeutic agents in order to identify mechanistically synergistic drug combinations that may be utilised in future clinical trials.

MATERIALS AND METHODS

Cells and cell culture

The human ovarian carcinoma cell line SKOV3 was maintained in DME with HEPES, 10% FCS and supplemented with glutamine. Stable NR-expressing SKOV3 cells (SKOV3NR) generated by infection with a retrovirus vector carrying the gene for E. coli bacterial nitroreductase were the kind gift of Dr PF Searle (University of Birmingham, UK).

Detection of NR and caspases by Western blotting

Cells were harvested, washed once in ice-cold PBS, pelleted by centrifugation and pellets lysed for 20 min on ice. Samples were pelleted at 13 000 rpm at 4°C and lysates decanted and stored at −70°C. Protein concentrations of total cell lysates were determined using a Biorad (Hercules, CA, USA) assay. Total cell lysate protein (100 μg) was separated by SDS–PAGE and electroblotted onto nitrocellulose. Membranes were blocked with 5% milk in PBS at room temperature for one h, at which time 5 μg ml−1 propidium iodide was added. Samples were analysed immediately on a Coulter EPICS XL flow cytometer. A two-dimensional dot plot was generated of Syto 16 fluorescence vs propidium iodide fluorescence. Syto 16 is only taken up by viable cells and propidium iodide only enters cells whose membranes have become permeabilised, therefore this technique distinguishes between viable cells (syto 16 +ve, propidium iodide −ve), apoptotic cells (syto 16 −ve, propidium iodide −ve) and necrotic cells (syto 16 −ve, propidium iodide +ve) (Schuurhuis et al., 1997). Data for 104 cells were collected for each sample and prior to data collection cell debris was excluded by setting a gate on a forward vs side scatter two-dimensional dot plot.

Caspase inhibitors

The cell-permeable caspase inhibitors IETD-FMK, LEHD-FMK, DEVD-FMK and ZVAD-FMK (Calbiochem, UK) were added to cells for 1 h prior to treatment with either CB1954 or chemotherapeutic drugs. Initially, a range of concentrations (1–200 μM) was tested and from these experiments a concentration of 50 μM was chosen for experiments in this study.

MTT assay

Cells were plated out at a density of 5 × 104 cells ml−1 in 96-well plates and allowed to attach overnight prior to treatment. Following treatment, 20 μl of 10 mg ml−1 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma) in PBS were added to each well and incubated for 4 h at 37°C, and the formazan crystals formed were dissolved in DMSO. The absorbance was recorded at 550 nm.

Analysis of the cytotoxic effect of CB1954 in combination with other chemotherapeutic agents

The effect of drug combinations was calculated according to the median effect principle described by Chou and Talalay (1984). Firstly, the dose–response curves for the cytotoxic effects of CB1954 and a panel of other drugs (cisplatin, 5-fluorouracil (5-FU), topotecan, doxorubicin, paclitaxel, gemcitabine) in SKOV3 cells either stably expressing NR, or expressing NR delivered by an adenovirus vector, for each agent singly and in combination were constructed.

The median effect principle of mass action states that

\[ f_u/f_a = (D/D_m)_m \]

where \( D \) is the drug dose, \( D_m \), the drug dose required for 50% cell kill, \( f_a \), the cell fraction affected, \( f_u \), the cell fraction unaffected, and \( m \) the coefficient of sigmoidicity.

This equation can be linearised by taking the logarithm of both sides so that \( y = \log(f_u/f_a) \) is plotted with respect to \( x = \log(D) \). From this, \( m \) and \( D_m \) can be derived. Note that the linear correlation coefficient, \( r \), describes the conformity of the data to the median effect principle. These data can then be used to determine the ‘combination index’ (CI), using the equation:

\[ CI = (D_1)/(D_x)_1 + (D_2)/(D_x)_2 \]

where \( (D_1)/(D_x)_1 \) and \( (D_2)/(D_x)_2 \) in combination kill \( x \% \) of cells, and \( (D_1) \) and \( (D_2) \) are the doses of each drug alone that kill \( x \% \) of cells. If CI < 1, = 1 or > 1, then synergism, additive effect or antagonism is indicated, respectively. So, if the combined observed effect is greater than the calculated additive effect, synergism is indicated.

The validity of this methodology was demonstrated by confirmation of the previously reported synergistic interaction between cisplatin and 5-FU (data not shown) (Shirasaka et al., 1993; Tsai et al., 1993).
RESULTS

The mode of cell death induced by CB1954 is predominantly apoptosis

The SKOV3 ovarian carcinoma cell line was either selected to stably express NR after retroviral transduction or infected with RAd-NR to produce transient NR expression. A comparison of the levels of NR expression showed that RAd-NR was able to deliver NR in a dose-dependent manner successfully with a virus dose of moi 10 resulting in similar levels of NR expression to that seen in the stably expressing cell line (Figure 1A). Further, NR sensitised SKOV3 cells to the prodrug CB1954 as measured by MTT assay, the amount of cell death correlating with the level of NR expression (Figure 1B).

Parental SKOV3 cells and SKOV3NR cells were treated with CB1954 over a range of concentrations. After 48 h, FACS analysis was performed to determine the degree of cell death induced and the relative amounts of apoptosis and necrosis. Figure 2B demonstrates that the mode of cell death induced by activated CB1954 in this setting was predominantly apoptosis, in common with a range of other chemotherapeutic agents (data not shown and Milner et al., 2002). In addition, RAd-NR infected SKOV3 cells were treated with CB1954 and similar analysis was performed. This confirmed that apoptosis was the predominant form of cell death induced and that the degree of apoptosis increased in proportion with increasing NR expression and increasing CB1954 dose (Figure 2C and D). In the absence of NR, CB1954 was toxic only at very high concentration (Figure 2A).

Activated CB1954 initiates activation of caspase-8, -9 and -3

Stably expressing SKOV3NR cells were treated with a panel of drugs commonly used in the treatment of ovarian cancer and with CB1954 at doses sufficient to induce apoptosis in approximately 70% of the cells. Western blot analysis for caspase-8, -9, and -3 revealed that the active form of each caspase could be clearly detected following treatment with all drugs including activated CB1954 (Figure 3A). However, in the absence of NR, CB1954 was unable to initiate apoptosis or activate any of these caspases (Figure 3A).

SKOV3 cells transiently expressing NR were also treated with CB1954 to induce high levels of apoptosis and similar Western blots were performed. Again, activation of caspase-8, -9, and -3 was seen. RAd-NR infection alone or CB1954 treatment of cells infected with a control adenovirus vector did not result in apoptosis or caspase activation (Figure 3B).

The relative contribution of caspases to the induction of apoptosis differs between RAd-NR infected and stable NR-expressing cells treated with CB1954, and between CB1954 and other chemotherapeutic agents

To determine whether the caspase activation seen in Figure 3 is essential for the mechanism of CB1954 induced cell death, stably expressing SKOV3NR cells were treated with CB1954 or one of a range of other drugs either in the presence or absence of specific inhibitors of caspase-3, -8, or -9, or a broad-spectrum caspase inhibitor, ZVAD-FMK. We have previously shown that at a concentration of 50 μM, DEVD-FMK (caspase-3 inhibitor), IETD-FMK (caspase-8 inhibitor) and LEHD-FMK (caspase-9 inhibitor) work in a specific manner (Milner et al., 2002). Therefore, this concentration was used for all the inhibitors in these experiments. Figure 4 shows the levels of cell death induced at 48 h by either drugs alone or when cells were preincubated with the inhibitors for 1 h prior to drug treatment.

Pretreatment with the broad-spectrum ZVAD inhibited apoptosis induced by activated CB1954 or by the other drugs used, confirming that apoptosis was caspase-dependent. In addition, pretreatment with each of the specific caspase inhibitors alone resulted in a significant reduction in the level of apoptosis induced by all the conventional cytotoxic drugs (Figure 4C, D and data not shown). However, pretreatment of stably expressing SKOV3NR cells with individual inhibitors alone was not sufficient to decrease CB1954-induced apoptosis, although this was significantly reduced by a combination of caspase-8 and -9 inhibitors. Apoptosis induced by CB1954 after RAd-NR infection was again inhibited by ZVAD. However, in this setting, the specific caspase-9 inhibitor (but not the caspase-8 inhibitor) also resulted in a partial reduction in the level of apoptosis, although a more profound inhibition resulted from combined pretreatment with caspase-8 and -9 inhibitors.

Combination treatment with CB1954 plus 5-FU causes enhanced tumour cell kill

As the above experiments indicated that apoptotic pathways and, specifically, the relative contribution of caspases activated by CB1954 differ from those initiated by other cytotoxic agents, it was of interest to determine whether combining CB1954 with any of these agents could cause an increase in cell death.

Stably expressing SKOV3NR cells were treated with CB1954 simultaneously with one of 5-FU, cisplatin, topotecan, doxorubicin, paclitaxel or gemcitabine over a range of drug concentrations. After 48 h, cell viability was assessed using the MTT assay. These
data were then used to calculate 'CI' plots to assess whether drug combinations were synergistic, additive or antagonistic. It was demonstrated that CB1954 in combination with 5-FU produced a synergistic enhancement of cell killing over a wide range of drug concentrations in both SKOV3NR cells and SKOV3 cells infected with RAd-NR. Of note, in the absence of NR, CB1954 did not potentiate 5-FU cytotoxicity. The addition of cisplatin, topotecan, doxorubicin, paclitaxel or gemcitabine to CB1954 resulted in, at best, additive cell killing and in some cases was even antagonistic (Figure 5 and data not shown). Similar results, specifically demonstrating synergy between activated CB1954 and 5-FU, have been obtained in human colon cancer cell lines (WiDr and SW480, data not shown).

Figure 2  Analysis of the mode of cell death induced by activated CB1954. (A) SKOV3 and stable NR expressing SKOV3 cells were treated with CB1954, cisplatin or 5-fluorouracil at doses sufficient to cause apoptosis in approximately 70% of cells (confirmed on samples prepared in parallel and analysed by FACS, data not shown). The dose of CB1954 used to treat parental SKOV3 cells was that which induced 70% apoptosis in NR-expressing cells. At this dose, no apoptosis was observed in the parental cells. After 48 h, the activation of caspase-3, -8 and -9 was assessed by Western blot analysis. Antibodies able to recognise both proform and active form of each caspase were used. Lanes 1–4, parental SKOV3 cells; lanes 5–8, stable NR expressing cells. Lanes 1 and 5, no drug; lanes 2 and 6, CB1954 10 μM; lanes 3 and 7, cisplatin 10 μM; lanes 4 and 8, 5-FU 500 μM. (B) SKOV3 cells were infected with RAd-NR (moi 10) or control adenovirus, RAd-35 (moi 10). After 48 h, cells were treated with CB1954 10 μM. After a further 48 h, caspase cleavage was assessed as in (A). Lane 1, untreated control; lane 2, CB1954 alone; lane 3, RAd-35 + CB1954; lane 4, RAd-NR alone; lane 5, RAd-NR + CB1954.
Experimental Therapeutics

DISCUSSION

In this study, we have investigated the mechanism of cell death induced by the VDEPT combination of NR and CB1954 in ovarian carcinoma cells and have demonstrated a synergistic interaction between activated CB1954 and 5-FU.

In common with a range of cytotoxic drugs with diverse mechanisms of action, cell death induced by activated CB1954 was predominantly apoptotic rather than necrotic. This distinction is important as it is thought that apoptotic cell death may not be optimal in generating immune responses to tumour antigens, which might enhance tumour cell killing in vivo (Melcher et al, 1999; Steinman et al, 2000). So, immune-mediated bystander killing in vivo may be enhanced by combined NR/CB1954 gene therapy with immunostimulatory molecules such as GM-CSF (Green et al, 2003).

Apoptosis induced by activated CB1954 was dependent upon caspase activation as indicated by the effect of the broad-spectrum caspase inhibitor, ZVAD. However, the relative contribution of caspases to CB1954-induced apoptosis differed from other cytotoxic drugs. Thus, inhibition of either caspase-3, -8 or -9 alone was effective in reducing levels of apoptosis induced by all the conventional cytotoxic drugs tested suggesting that these are critical effectors of apoptosis. However, when CB1954 was activated in cells stably expressing NR, although caspase-3, -8 and -9 were cleaved, inhibition of either one alone was not sufficient to block apoptosis. Inhibition of caspase-8 and -9 together did significantly reduce apoptosis. This indicates that activated CB1954 may activate caspase-8 and -9 separately, either one of which is sufficient for apoptosis, rather than caspase-9 cleavage occurring downstream of caspase-8 via bid cleavage, as reported for other apoptotic stimuli. This is consistent with previous reports indicating that deficiency of certain caspases can result in compensatory activation of alternative caspase pathways, suggesting a degree of redundancy in death activating pathways (Zheng et al, 2000).
Interestingly, a different pattern was observed when NR was delivered via an adenovirus vector, with caspase-9 inhibition resulting in a partial reduction in apoptosis. This may be explained by the effect of the adenovirus vector upon anti-apoptotic cellular pathways. Indeed, we have demonstrated that such vectors activate the NF-kB pathway which in turn upregulates expression of antiapoptotic cellular pathways (manuscript submitted). Other studies have reported that NF-kB inducible factors can act by inhibiting caspase-8 activity downstream of its cleavage to the active form (Wang et al, 1998; You et al, 2001). Therefore, the adenovirus vector may activate cellular pathways resulting in caspase-8 inhibition, so that the additional inhibition of caspase-9 may reduce CB1954-induced apoptosis. These effects may be important, since adenovirus delivery of prodrug-activating enzymes or other cytotoxic agents is a major focus of cancer gene therapy protocols. These data will prove useful in the further development of this novel therapy and will facilitate the rational study of NR/CB1954 in combination with other novel anticancer strategies or with conventional chemotheraphy.

The current study has addressed the effect of CB1954 given in combination with other drugs to investigate whether potentially synergistic combinations could be identified. Using the median effect principle of mass action, it was possible to calculate the expected effect of a combination of drugs based on knowledge of their individual effects. This was then compared to the observed effect achieved by the drug combination. The ratio of the expected to the observed effect is the 'CI' so that CI<1 indicates a synergistic interaction, CI=1 indicates an additive effect and CI>1 indicates antagonism. CB1954 treatment of SKOV3 cells stably expressing NR in combination with cisplatin, topotecan, doxorubicin, paclitaxel or gemcitabine demonstrated at best additive and in some cases even antagonistic interaction. Conversely, the combination of CB1954 with 5-FU was found to be synergistic across a wide range of doses. This effect was observed whether NR was expressed stably or delivered via an adenovirus vector. These data suggest that, if VDEPT is to be used in combination with conventional chemotheraphy, the clinical outcome may be critically dependent upon the drugs chosen. As early phase clinical trials of other VDEPT systems or conditionally replicating adenoviruses in combination with conventional chemotherapy have reported this to be a safe, feasible approach with promising evidence of efficacy, the data presented here will prove useful in the rational design of future clinical trials of VDEPT using NR/CB1954 (Khuri et al, 2000).

It will also be important to carry out further research to determine why NR/CB1954 can synergise with some drugs, but have an inhibitory effect with others. Since there are differences in the pathways upstream of caspase cleavage activated by drugs with different intracellular targets, this may determine the interaction of drug combinations. Alternatively, synergy may be related to effects on cell cycle progression (given that 5-FU is a cell cycle-specific drug), effects on mechanisms of drug resistance, interference with activation/inactivation of active metabolites, effects on DNA repair mechanisms or other undefined mechanisms.

REFERENCES
Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. *Eur J Cancer* 31A(13–14): 2362 – 2370
Chou TC, Talalay P (1984) Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul* 22: 27 – 55
Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Kerr DJ, Young LS, Searle PF, Kerr DJ, Palmer DH (1999) Chemosensitivity of solid tumors xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. *Cancer Gene Ther* 7(9): 721 – 731
Eischen CM, Nettleman DS, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L, Harris PA, Ferry D, Kerr DJ (2001) Virus-directed, enzyme prodrug therapy with nitromidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. *Clin Cancer Res* 7(9): 2662 – 2668
Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, Kerr DJ, Wrighton CJ (2000) Expression of *Escherichia coli* B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. *Cancer Gene Ther* 7(5): 721 – 731
Eisgen CM, Kotke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH (1997) Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. *Blood* 90(3): 935 – 943
Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/1-FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. *Nat Med* 2(5): 574 – 577
Fulda S, Los M, Friesen C, Debatin KM (1998a) Chemosenstivitity of solid tumor cells in vitro is related to activation of the CD95 system. *Int J Cancer* 76(1): 105 – 114
Fulda S, Saffadi C, Pietsch T, Krammer PH, Peter ME, Debatin KM (1998b) Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. *Cell Death Differ* 5(10): 884 – 893
Fulda S, Sievert H, Friesen C, Herr I, Debatin KM (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. *Cancer Res* 57(17): 3823 – 3829
Fulda S, Strauss G, Meyer E, Debatin KM (2000) Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. *Blood* 95(1): 301 – 308
Gamen S, Anel A, La Sierra P, Alava MA, Martinez-Lorenzo MJ, Pinheiro A, Naval J (1997) Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. *FEBS Lett* 417(3): 360 – 364
Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS (2003) Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. *Int J Cancer* 104(1): 104 – 112
Khuri FR, Menunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH (2000) A controlled trial of intratumoral ONX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* 6(8): 879 – 885
Knox RJ (ed.) (1998) Targeted Anti-cancer Therapies: are They ADEPT or INEPT? Greenwich, United Kingdom: The University of Greenwich Inaugural Lecture Series
Link Jr CJ, Levy JP, McCann L, Moorman DW (1997) Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. *J Surg Oncol* 64(4): 289 – 294
McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, Searle PF (1998) Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered *E. coli* nitroreductase and CB1954. *Gene Therapy* 5(8): 1061 – 1069
Melcher A, Gough M, Todryk S, Vine R (1999) Apoptosis or necrosis for tumor immunotherapy: what’s in a name? *J Mol Med* 77(12): 824 – 833
Michoud O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT (1997) Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. *J Natl Cancer Inst* 89(11): 783 – 789
Milner AE, Palmer DH, Hodgkin EA, Elipoulos AG, Knox PG, Poole CJ, Kerr DJ, Young LS (2002) Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. *Cell Death Differ* 9(3): 287 – 300
Ruiz-Ruiz MC, Lopez-Rivas A (1999) p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells. *Cell Death Differ* 6(3): 271 – 280

© 2003 Cancer Research UK

British Journal of Cancer (2003) 89(5), 944 – 950

Experimental Therapeutics
Schuurhuis GJ, Oberink JW, Bontje PM, Broxterman HJ (1997) The PGP-specific combination Syto16/PSC833 detects early apoptosis in CD34 positive progenitor cells. *Exp Hematol* 25: 754

Shirasaka T, Shimamoto Y, Ohshima H, Saito H, Fukushima M (1993) Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models *in vivo*. *Cancer Chemother Pharmacol* 32(3): 167 – 172

Steinman RM, Turley S, Mellman I, Inaba K (2000) The induction of tolerance by dendritic cells that have captured apoptotic cells. *J Exp Med* 191(3): 411 – 416

Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM (1999) Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. *J Biol Chem* 274(8): 5053 – 5060

Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D’Alessandro N, Papoff G, Ruberti G, Rausa L (1998) The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. *Cell Death Differ* 5(9): 735 – 742

Tsai CM, Hsiao SH, Frey CM, Chang KT, Perng RP, Gazdar AF, Kramer BS (1993) Combination cytotoxic effects of cis-diaminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. *Cancer Res* 53(5): 1079 – 1084

Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R (1997) Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. *Cancer Res* 57(16): 3331 – 3334

Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science* 281(5383): 1680 – 1683

Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, Mountain A, Young LS, Kerr DJ, Searle PF (2000) Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of *E. coli* nitroreductase. *Int J Cancer* 86(6): 848 – 854

Wilkinson GW, Akigg A (1992) Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. *Nucleic Acids Res* 20(9): 2233 – 2239

You Z, Ouyang H, Lopatin D, Polver PJ, Wang CY (2001) Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. *J Biol Chem* 276(28): 26398 – 26404

Zheng TS, Hunot S, Kuida K, Momoi T, Srinivasan A, Nicholson DW, Lazebnik Y, Flavell RA (2000) Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. *Nat Med* 6(11): 1241 – 1247